Regulations & Policy
WHO prequalifies new dengue vaccine
IMT News Desk
WHO prequalifies new dengue vaccine
IMT News Desk
WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity
A new vaccine for dengue received prequalification from the World Health Organization (WHO). TAK-003 is the second dengue vaccine to be prequalified by WHO. Developed by Takeda, it is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.
WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity. The vaccine should be administered in a two-dose schedule with a three-month interval between doses.
“The prequalification of TAK-003 is an important step in the expansion of global access to dengue vaccines, as it is now eligible for procurement by UN agencies including UNICEF and PAHO,” said Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification. “With only two dengue vaccines to date prequalified, we look forward to more vaccine developers coming forward for assessment so that we can ensure vaccines reach all communities who need it.”
The WHO prequalification list also includes CYD-TDV vaccine against dengue developed by Sanofi Pasteur.
Recommended
